Related Experiment Videos
Estimation of dynamical model parameters taking into account undetectable marker values.
Rodolphe Thiébaut1, Jérémie Guedj, Hélène Jacqmin-Gadda
1INSERM E0338 Biostatistics, Bordeaux 2 University, Bordeaux, France. rt@isped.u-bordeaux2.fr
BMC Medical Research Methodology
|August 2, 2006
Summary
A new method accurately estimates hepatitis C virus (HCV) dynamics by accounting for undetectable viral load measurements. This approach provides unbiased parameter estimates, crucial for understanding treatment efficacy in clinical trials.
Area of Science:
- Mathematical modeling
- Virology
- Pharmacokinetics
Background:
- Mathematical models are essential for studying infectious agent dynamics, like hepatitis C virus (HCV).
- Estimating model parameters often uses standard least-squares, but left-censored data (undetectable viral load) pose challenges.
- Hierarchical models and methods addressing left-censoring are needed for accurate parameter estimation.
Purpose of the Study:
- To propose and validate a method for estimating parameters in nonlinear mixed-effects models with left-censored data.
- To assess the impact of this method on parameter estimation in hepatitis C virus (HCV) dynamics.
- To compare the proposed method with traditional approaches using simulations and a clinical trial.
Main Methods:
- A full likelihood approach was employed, differentiating between observed and left-censored measurements.
- A lognormal distribution was assumed for the outcome variable (viral load).
- Parameters were estimated using standard statistical software for the analytical solution of differential equations.
Main Results:
- Ignoring left-censoring led to significant parameter bias (up to 133%) in simulations.
- The proposed method reduced relative bias on fixed effects to ≤2%.
- Clinical trial data showed significant differences in parameter estimates, particularly for infected cell death rates, impacting treatment efficacy assessment.
Conclusions:
- The proposed method provides unbiased parameter estimates when the assumed distribution (e.g., lognormal) is correct.
- This approach is practical and can be implemented using standard statistical software.
- Accurate estimation, especially with left-censored data, is vital for reliable interpretation of anti-HCV drug clinical trials.